(FULC) Fulcrum Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3596161097

FULC: Muscle, Blood, Genetic, Disorder, Therapy

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company focuses on advancing treatments for rare and debilitating conditions, leveraging its expertise in small molecule therapeutics and fetal hemoglobin induction.

Its lead product candidate, losmapimod, is a small molecule inhibitor currently in Phase III clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disorder characterized by progressive muscle weakness and degeneration. The company is also developing pociredir, a fetal hemoglobin inducer, which is in Phase I clinical trials for the treatment of sickle cell disease and beta-thalassemia, severe hematologic disorders requiring innovative therapeutic approaches.

Fulcrum has established strategic collaborations to expand its pipeline. It partners with Acceleron Pharma Inc. to identify targets in pulmonary diseases, MyoKardia, Inc. to develop therapies for genetic cardiomyopathies, and Sanofi to co-develop and commercialize losmapimod for FSHD. These collaborations underscore its commitment to addressing a broad range of rare and serious diseases, including neuromuscular, muscular, CNS, and hematologic disorders.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum Therapeutics operates at the intersection of genetics and drug development, aiming to deliver transformative therapies for patients with limited treatment options.

Ticker Symbol: FULC Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Pharmaceuticals

Average Volume 20d: 400301 Last Price: 3.24 SMA 20: 3.67 SMA 50: 4.09 SMA 200: 5.54 ATR: 0.26

Market Cap: 181.91M USD P/E: 0.00 P/E Forward: 0.00 P/B: 0.74 P/S: 2.27 RoE: -4.00

3-Month Forecast: Based on technical and fundamental analysis, FULC is expected to face headwinds in the near term. The stock is trading below its SMA20 and SMA50, indicating bearish momentum. However, the relatively low ATR suggests moderate volatility. Fundamentally, the negative RoE and low P/B ratio highlight challenges in valuation and profitability. Short-term price stabilization is possible if the company demonstrates progress in its clinical pipeline or announces favorable collaborations.

Additional Sources for FULC Stock

FULC Stock Overview

Market Cap in USD 170m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2019-07-18

FULC Stock Ratings

Growth 5y -75.4%
Fundamental -22.0%
Dividend 0.0%
Rel. Strength Industry -72.3
Analysts 3.29/5
Fair Price Momentum 2.25 USD
Fair Price DCF -

FULC Dividends

No Dividends Paid

FULC Growth Ratios

Growth Correlation 3m -88%
Growth Correlation 12m -70.5%
Growth Correlation 5y -67.8%
CAGR 5y -21.44%
CAGR/Max DD 5y -0.23
Sharpe Ratio 12m -0.65
Alpha -74.66
Beta -0.25
Volatility 82.51%
Current Volume 730.2k
Average Volume 20d 391.5k
What is the price of FULC stocks?
As of March 15, 2025, the stock is trading at USD 3.12 with a total of 730,246 shares traded.
Over the past week, the price has changed by -0.64%, over one month by -15.45%, over three months by -29.41% and over the past year by -72.09%.
Is Fulcrum Therapeutics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Fulcrum Therapeutics is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -21.99 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FULC as of March 2025 is 2.25. This means that FULC is currently overvalued and has a potential downside of -27.88%.
Is FULC a buy, sell or hold?
Fulcrum Therapeutics has received a consensus analysts rating of 3.29. Therefor, it is recommend to hold FULC.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 4
  • Sell: 1
  • Strong Sell: 0
What are the forecast for FULC stock price target?
According to ValueRays Forecast Model, FULC Fulcrum Therapeutics will be worth about 2.4 in March 2026. The stock is currently trading at 3.12. This means that the stock has a potential downside of -22.12%.
Issuer Forecast Upside
Wallstreet Target Price 5.7 81.7%
Analysts Target Price 5.7 81.7%
ValueRay Target Price 2.4 -22.1%